Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 8INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 3Plasma cell 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 48Gastrointestinal Stromal Tumors 26Leukemia 20Leukemia, Myeloid, Chronic-Phase 15Philadelphia Chromosome 9Leukemia, Myeloid 8Bone Marrow Diseases 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Hematologic Neoplasms 4Hematologic Diseases 4Blast Crisis 4Myeloproliferative Disorders 3Leukemia, Myeloid, Acute 3Hypereosinophilic Syndrome 3Glioblastoma 3Digestive System Neoplasms 3Bronchiolitis Obliterans Syndrome 3Recurrence 2Prostatic Neoplasms 2Neurofibrosarcoma 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myeloid, Accelerated Phase 2Dermatofibrosarcoma 2Chordoma 2Brain Neoplasms 2Adenocarcinoma 2Urogenital Neoplasms 1

Interventions

Azacitidine 142Cytarabine 109venetoclax 94fludarabine 35Daunorubicin 34Decitabine 32Idarubicin 26gilteritinib 24Cyclophosphamide 21quizartinib 15midostaurin 15Mitoxantrone 14Etoposide 14Granulocyte Colony-Stimulating Factor 12Gemtuzumab 11CPX-351 11decitabine and cedazuridine drug combination 10Drug Therapy 10cc-486 9Filgrastim 9Clofarabine 9ivosidenib 8Injections 8Dexamethasone 8pevonedistat 7fludarabine phosphate 7AP 1903 reagent 7posaconazole 6magrolimab 6glasdegib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid, Acute × Imatinib Mesylate × Clear all
NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Sumitomo Pharma America, Inc.

Phase 1 Completed
15 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT00171223 2021-07-22

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

Novartis

Phase 2 Completed
532 enrolled 14 charts
LymphoidMyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00171249 2021-07-22

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

Novartis

Phase 2 Completed
293 enrolled 12 charts
LymphoidMyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡